Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
NCT02071134
Recruiting
The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS System in the treatment of Parkinson's disease. The utilization of Image Guided Programming (IGP), and other commercially available programming features, used as planning tools for the programming of patients with Boston Scientific's Vercise DBS System are also evaluated. Additionally, the utilization of the DBS Illumina 3D feature that may be... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Neurology and Pain Specialty, Aliso Viejo, California +81 locations
Conditions: Parkinson's Disease
Register for Updates
Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment
NCT04179162
Recruiting
This study will test the safety of BCG and gemcitabine in people who have BCG-relapsing Non-Muscle Invasive Bladder Cancer (NMIBC). The researchers will test increasing doses of gemcitabine to find the highest dose that causes few or mild side effects when combined with BCG. The study will also look at whether this combination of drugs is effective in treating BCG-relapsing NMIBC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Hartford Healthcare (Data Collection), Hartford, Connecticut +7 locations
Conditions: Non-Muscle Invasive Bladder Cancer (NMIBC)
Register for Updates
Experimental Manipulation of Sleep and Circadian Rhythms and the Role Played on Reward Function in Teens
NCT04792697
Recruiting
Adolescence is a time of heightened reward sensitivity and greater impulsivity. On top of this, many teenagers experience chronic sleep deprivation and misalignment of their circadian rhythms due to biological shifts in their sleep/wake patterns paired with early school start times. Many studies find that this increases the risk for substance use (SU). However, what impact circadian rhythm and sleep disruption either together or independently have on the neuronal circuitry that controls reward a... Read More
Gender:
ALL
Ages:
Between 13 years and 15 years
Trial Updated:
04/02/2025
Locations: Western Psychiatric Hospital, Pittsburgh, Pennsylvania
Conditions: Delayed Sleep Phase Syndrome
Register for Updates
Breaking up Sedentary Time to Improve Glucose Control in a Population at Risk for Developing Type 2 Diabetes
NCT05041491
Recruiting
Newly released guidelines recommend increased physical activity (PA) and reduced sedentary behaviors (SB) to improve glycemia and prevent the onset and progression of type 2 diabetes (T2D). Typically, 30-60 min bouts of PA are advocated per day. Although this approach increases PA, it does not decrease the length of the sedentary periods through the day. This is important because recent epidemiological data suggest that frequently interrupting sedentary time improves glucose control even in peop... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
04/02/2025
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado
Conditions: Pre-diabetes
Register for Updates
Naturalistic Sleep Assessed by Wearable Devices in Parkinson Disease
NCT05348837
Recruiting
The cardinal motor features of Parkinson's disease (PD) include bradykinesia, rest tremor, and rigidity. Though non-motor features have been recognized for centuries, only recently has the prevalence and impact of non-motor symptoms become the focus of intense study. Disturbances of sleep are among the most common non-motor manifestations of PD; approximately two-thirds of PD patients experience sleep dysfunction of some kind. Given that sleep contributes to the regulation of many physiological... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/02/2025
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado
Conditions: Parkinson Disease
Register for Updates
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
NCT05552222
Recruiting
The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: City of Hope Cancer Center, Duarte, California +202 locations
Conditions: Multiple Myeloma
Register for Updates
Impact of Resident Participation in Post-ICU Follow Up Clinic
NCT05713669
Recruiting
This study is being conducted to describe the impact of a meeting between patients that were admitted to the intensive care unit (ICU) and a provider that cared for the patients during the period of critical illness. The study team is aiming to describe the effect this meeting has on the physician that previously cared for the patient. The study team hypothesizes that facilitating involvement in post-ICU clinic and creating longitudinal relationships between providers of critical care and survi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Professional Burnout
Register for Updates
Intervention for Virologic Suppression in Youth
NCT05877729
Recruiting
The goal of this randomized clinical trial is to test the effect of a technology-based intervention with an Adaptive Treatment Strategy (ATS) among youth living with HIV (YLWH) (18-29 years old). This piloted and protocolized intervention combines: (1) brief weekly sessions with a counselor via a video-chat platform (video-counseling) to discuss mental health (MH), substance use (SU), HIV care engagement, and other barriers to care; and (2) a mobile health application (app) to address barriers s... Read More
Gender:
ALL
Ages:
Between 18 years and 29 years
Trial Updated:
04/02/2025
Locations: Division of Prevention Science, Center for AIDS Prevention Studies (CAPS), San Francisco, California
Conditions: HIV/AIDS, Young Adult, Mobile Health, Mental Health Issue, Substance Use
Register for Updates
Early Point-of-Service Social and Behavioral Determinants of Health (SBDOH) Screening and Enhanced Navigation on Care Delivery for Patients With Breast Cancer
NCT06019988
Recruiting
The overarching goal of this project is to optimize the collection of social and behavioral determinants of health (SBDOH) for patients with a pathological diagnosis of breast cancer at Penn Medicine. The investigators will measure rates of SBDOH data collection by modality and rates of referral to and uptake of social support services, time to evaluation, staff time, acceptability, patient-centered communication, medical mistrust, and clinician acceptability.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Breast Cancer, Social Determinants of Health (SDOH)
Register for Updates
A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer
NCT06116786
Recruiting
The purpose of this study is to determine a safe and tolerable dose(s) of JNJ-86974680 for further research in combination with cetrelimab and radiation therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Roswell Park Comprehensive Cancer Center, Buffalo, New York +9 locations
Conditions: Carcinoma, Non-small-Cell Lung
Register for Updates
Comparing Telephone Symptom Monitoring Interventions for Managing Symptoms and Psychological Distress During Oral Anti-Cancer Treatment
NCT06279013
Recruiting
In this clinical trial, symptom monitoring (interactive voice response \[IVR\] is compared to automated telephone symptom management \[ATSM\] and telephone interpersonal counseling \[TIPC\]) for reducing symptom burden and psychological distress (depressive and anxiety symptoms) among people receiving oral anti-cancer treatment. Symptoms are the number one driver of treatment interruptions and unscheduled health services use. To reduce the risk of these events, symptom monitoring and management... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Cancer Center at Saint Joseph's, Phoenix, Arizona +25 locations
Conditions: Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm
Register for Updates
Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer
NCT06493019
Recruiting
A single arm phase II study of pembrolizumab, carboplatin, paclitaxel, and radiation for the treatment of early-stage anal cancer. There are 2 treatments phases and then surveillance. The first treatment phase is the chemoradiation phase (Cycle 1-6, weekly cycles) which is followed by the maintenance phase (Cycle 7-14, 6 week cycles).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey +1 locations
Conditions: Anal Cancer
Register for Updates